These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1671 related items for PubMed ID: 11585766

  • 1. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER.
    Cancer Res; 2001 Oct 01; 61(19):7277-81. PubMed ID: 11585766
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER.
    Genes Chromosomes Cancer; 1998 Jul 01; 22(3):200-9. PubMed ID: 9624531
    [Abstract] [Full Text] [Related]

  • 3. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER.
    Proc Natl Acad Sci U S A; 2001 Jun 19; 98(13):7504-9. PubMed ID: 11390984
    [Abstract] [Full Text] [Related]

  • 4. [Development of human renal cell carcinoma (RCC)--the responsible genes for the development of hereditary and sporadic human RCCs].
    Shuin T, Kamata M, Ashida S.
    Gan To Kagaku Ryoho; 2002 Oct 19; 29(10):1719-25. PubMed ID: 12402420
    [Abstract] [Full Text] [Related]

  • 5. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
    Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.
    Oncol Rep; 2004 Oct 19; 12(4):805-10. PubMed ID: 15375503
    [Abstract] [Full Text] [Related]

  • 6. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
    Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ, Maher ER, Latif F.
    Eur J Cancer; 2002 Aug 19; 38(12):1585-92. PubMed ID: 12142046
    [Abstract] [Full Text] [Related]

  • 7. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.
    Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, Maher ER, Latif F.
    Mol Pathol; 2000 Jun 19; 53(3):137-44. PubMed ID: 10897333
    [Abstract] [Full Text] [Related]

  • 8. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC, Walsh S, Hewson K, Green EK, Brinke A, Green PM, Gianelli F, Eng C, Maher ER.
    Genes Chromosomes Cancer; 1999 Sep 19; 26(1):20-8. PubMed ID: 10441001
    [Abstract] [Full Text] [Related]

  • 9. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
    Lovell M, Lott ST, Wong P, El-Naggar A, Tucker S, Killary AM.
    Cancer Res; 1999 May 01; 59(9):2182-9. PubMed ID: 10232606
    [Abstract] [Full Text] [Related]

  • 10. Inactivation of BHD in sporadic renal tumors.
    Khoo SK, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K, Ludlow J, Knapp R, Giraud S, Richard S, Nordenskjöld M, Teh BT.
    Cancer Res; 2003 Aug 01; 63(15):4583-7. PubMed ID: 12907635
    [Abstract] [Full Text] [Related]

  • 11. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
    Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM.
    Cancer Res; 2003 Jul 01; 63(13):3724-8. PubMed ID: 12839965
    [Abstract] [Full Text] [Related]

  • 12. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.
    Sükösd F, Kuroda N, Beothe T, Kaur AP, Kovacs G.
    Cancer Res; 2003 Jan 15; 63(2):455-7. PubMed ID: 12543802
    [Abstract] [Full Text] [Related]

  • 13. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.
    Lemm I, Lingott A, Pogge v Strandmann E, Zoidl C, Bulman MP, Hattersley AT, Schulz WA, Ebert T, Ryffel GU.
    Mol Carcinog; 1999 Apr 15; 24(4):305-14. PubMed ID: 10326868
    [Abstract] [Full Text] [Related]

  • 14. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
    Singh RB, Amare Kadam PS.
    Urol Oncol; 2013 Oct 15; 31(7):1333-42. PubMed ID: 21962529
    [Abstract] [Full Text] [Related]

  • 15. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
    Velickovic M, Delahunt B, Störkel S, Grebem SK.
    Cancer Res; 2001 Jun 15; 61(12):4815-9. PubMed ID: 11406557
    [Abstract] [Full Text] [Related]

  • 16. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
    Meléndez B, Rodríguez-Perales S, Martínez-Delgado B, Otero I, Robledo M, Martínez-Ramírez A, Ruiz-Llorente S, Urioste M, Cigudosa JC, Benítez J.
    Hum Genet; 2003 Feb 15; 112(2):178-85. PubMed ID: 12522559
    [Abstract] [Full Text] [Related]

  • 17. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.
    Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493
    [Abstract] [Full Text] [Related]

  • 18. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER.
    Cancer Res; 2005 Jun 01; 65(11):4598-606. PubMed ID: 15930277
    [Abstract] [Full Text] [Related]

  • 19. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H, Weirich G, Brieger J, Glavac D, Rödl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Störkel S, Rotter M, Masera A, Gugeler N, Decker HJ.
    Cancer Res; 2000 Apr 01; 60(7):1942-8. PubMed ID: 10766184
    [Abstract] [Full Text] [Related]

  • 20. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW, Maher ER, Minna JD, Latif F.
    Oncogene; 2003 Mar 13; 22(10):1580-8. PubMed ID: 12629521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.